783
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis

ORCID Icon & ORCID Icon
Page 873 | Received 06 Apr 2023, Accepted 13 Apr 2023, Published online: 19 Apr 2023

References

  • Francesc C, Sander HW, Fernández S. Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis. Expert Opin Pharmacother. 2023;24. just-accepted. DOI:10.1080/14656566.2023.2192867
  • Vanoli F, Mantegazza R. What are the pharmacotherapeutic con- siderations for the treatment of myasthenia gravis? Expert Opin Pharmacother. 2022;23:1471–1474.
  • Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837–841.
  • Karelis G, Balasa R, De Bleecker JL, et al. A Phase 3 multicenter, prospective, open-label efficacy and safety study of immune glo- bulin (Human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81:223–230.
  • Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–2023.
  • Murai H. J apanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Immunol. 2015;6(1):21–31.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.